Clonidine Hcl
Brand names: Clonidine Hcl, Clonidine Hcl Er
At a glance
- Medicare prescriptions, 2024
- 2,694,053
- Medicare drug cost
- $17.7M
- Average cost per prescription
- $6.56
- Clinicians who prescribed it
- 90,110
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
QLONILIK TM (clonidine hydrochloride) oral solution is indicated for the treatment of hypertension, to lower blood pressure in adults. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the American College of Cardiology/American Heart Association (ACC/AHA). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in…
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 25.9%
- Internal Medicine 22.6%
- Nurse Practitioners 15.6%
- Cardiology 6.4%
- Psychiatric Nurse Practitioners 6.3%
- Psychiatry 5.2%
- Physician Assistants 4.6%
- Nephrology (Kidney) 4.0%
- Interventional Cardiology 2.1%
- General Practice 2.1%
- Geriatric Medicine 1.1%
- Child & Adolescent Psychiatry 0.5%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 13% from 2019 to 2024.
Biggest change by state since 2019
- Utah +14%
- Connecticut +9%
- Rhode Island +9%
- Idaho +7%
- Montana +6%
- District of Columbia (smallest change) −26%
- South Carolina (smallest change) −25%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Cmp Pharma, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 0.05 mg | white solution | |
Stat Rx USA LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 0.1 mg | orange round tablet, 6 mm, scored to split in 2 | R127 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.